On the versatility of von Willebrand factor

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 5, Issue 1, 2013, Pages

  Rauch, Antoine ^a,b,c,d   Wohner, Nikolett ^a,b   Christophe, Olivier D ^a,b   Denis, Cécile V ^a   Susen, Sophie ^c,d   Lenting, Peter J ^a,b  

^a Dept Environ Med Natl Inst Publ HIth   (Norway)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN; VON WILLEBRAND FACTOR;

APOPTOSIS; BINDING AFFINITY; BINDING SITE; CELL PROLIFERATION; EFFECTOR CELL; HEMOSTASIS; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SHEAR STRESS; SMOOTH MUSCLE FIBER; VON WILLEBRAND DISEASE;

EID: 84897483560     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/mjhid.2013.046     Document Type: Review

References (186)

1. Willebrand EA. Über hereditäre Pseudohämophilie. Act Med Scand. 1931;76(4-6):521-550. http://dx.doi.org/10.1111/j.0954-6820.1931.tb18363.x
2. Nilsson IM, Blomback M, Jorpes E, Blomback B, Johansson S. v. Willebrand's Disease and its Correction with Human Plasma Fraction 1-0. Act Med Scand. 1957;159(3):179-188. http://dx.doi.org/10.1111/j.0954-6820.1957.tb00123.x
3. Owen WG. Big piece, little piece or: yes, factor VIII is a protein. J Thromb Haemostas. 2005;3(9):1905-1909. http://dx.doi.org/10.1111/j.1538-7836.2005.01247.x PMid:16102092
4. Bouma BN, Van Mourik JA. Unraveling the mystery of von Willebrand factor. J Thromb Haemostas. 2006;4(3):489-495. http://dx.doi.org/10.1111/j.1538-7836.2006.01813.x PMid:16460427
5. Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost. 2007;98(1):55-62. PMid:17597991
6. Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science. 1985;228(4706):1401-1406. http://dx.doi.org/10.1126/science.3874428 PMid:3874428
7. Lynch DC, Zimmerman TS, Collins CJ, et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell. 1985;41(1):49-56. http://dx.doi.org/10.1016/0092-8674(85)90060-1
8. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5(8):1839-1847. PMid:3019665 PMCid:1167049
9. Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A. 1985;82(19):6394-6398. http://dx.doi.org/10.1073/pnas.82.19.6394 PMid:2864688 PMCid:390722
10. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry. 1986;25(11):3171-3184. http://dx.doi.org/10.1021/bi00359a015 PMid:3524673
11. James PD, Lillicrap D. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. Am J Hematol. 2012;87 Suppl 1:S4-11. http://dx.doi.org/10.1002/ajh.23142 PMid:22389132
12. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24(3):123-134. http://dx.doi.org/10.1016/j.blre.2010.03.003 PMid:20409624
13. Schneppenheim R, Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost. 2011;9 Suppl 1:209-215. http://dx.doi.org/10.1111/j.1538-7836.2011.04324.x PMid:21781257
14. Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program. 2009:106-112. http://dx.doi.org/10.1182/asheducation-2009.1.106 PMid:20008188
15. Margulis T, David M, Maor N, et al. The von Willebrand factor in myocardial infarction and unstable angina: a kinetic study. Thromb Haemost. 1986;55(3):366-368. PMid:3092393
16. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332(10):635-641. http://dx.doi.org/10.1056/NEJM199503093321003 PMid:7845427
17. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation. 1998;98(4):294-299. http://dx.doi.org/10.1161/01.CIR.98.4.294 PMid:9711933
18. Folsom AR, Rosamond WD, Shahar E, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1999;100(7):736-742 http://dx.doi.org/10.1161/01.CIR.100.7.736 PMid:10449696
19. Whincup PH, Danesh J, Walker M, et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23(22):1764-1770. http://dx.doi.org/10.1053/euhj.2001.3237 PMid:12419296
20. Morange PE, Simon C, Alessi MC, et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004;109(11):1343-1348. http://dx.doi.org/10.1161/01.CIR.0000120705.55512.EC PMid:15023872
21. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-1397. http://dx.doi.org/10.1056/NEJMoa032804 PMid:15070788
22. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449-1459. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.722827 PMid:18347221
23. Sanders YV, Eikenboom J, de Wee EM, et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemostas. 2013; DOI:10.1111/jth.12194 http://dx.doi.org/10.1111/jth.12194
24. Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151-2156. http://dx.doi.org/10.1161/STROKEAHA.110.586289 PMid:20798373
25. van Schie MC, Wieberdink RG, Koudstaal PJ, et al. Genetic Determinants of Von Willebrand Factor Plasma Levels and the Risk of Stroke: The Rotterdam Study. J Thromb Haemost. 2012;10(4):899-908. http://dx.doi.org/10.1111/j.1538-7836.2012.04634.x PMid:22257027
26. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113(8):636-642. http://dx.doi.org/10.1016/S0002-9343(02)01345-1
27. Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol. 2010;149(6):824-833. http://dx.doi.org/10.1111/j.1365-2141.2010.08206.x PMid:20456358
28. Smith NL, Rice KM, Bovill EG, et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood. 2011;117(22):6007-6011. http://dx.doi.org/10.1182/blood-2010-10-315473 PMid:21163921 PMCid:3112044
29. Fuchs TA, Brill A, Wagner DD. Neutrophil Extracellular Trap (NET) Impact on Deep Vein Thrombosis. Arterioscler Thromb Vasc Biol. 2012;32(8):1777-1783. http://dx.doi.org/10.1161/ATVBAHA.111.242859 PMid:22652600
30. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345(8943):152-155. http://dx.doi.org/10.1016/S0140-6736(95)90166-3
31. Campos M, Buchanan A, Yu F, et al. Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study. Blood. 2012;119(8):1929-1934. http://dx.doi.org/10.1182/blood-2011-10-383661 PMid:22219226 PMCid:3293647
32. Lenting PJ, Casari C, Christophe OD, Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012;10(12):2428-2437. http://dx.doi.org/10.1111/jth.12008 PMid:23020315
33. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246. http://dx.doi.org/10.1146/annurev.cb.06.110190.001245 PMid:2275814
34. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. http://dx.doi.org/10.1146/annurev.biochem.67.1.395 PMid:9759493
35. Sadler JE. von Willebrand factor assembly and secretion. J Thromb Haemost. 2009;7 Suppl 1:24-27. http://dx.doi.org/10.1111/j.1538-7836.2009.03375.x PMid:19630761
36. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem. 1983;258(4):2065-2067. PMid:6600453
37. Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest. 1985;76(3):1102-1106. http://dx.doi.org/10.1172/JCI112064 PMid:2413071 PMCid:423998
38. Pannekoek H, Voorberg J. Molecular cloning, expression and assembly of multimeric von Willebrand factor. Baillieres Clin Haematol. 1989;2(4):879-896. http://dx.doi.org/10.1016/S0950-3536(89)80050-2
39. Springer TA. Biology and physics of von Willebrand factor concatamers. J Thromb Haemost. 2011;9 Suppl 1:130-143. http://dx.doi.org/10.1111/j.1538-7836.2011.04320.x PMid:21781248
40. Zhou YF, Eng ET, Nishida N, Lu C, Walz T, Springer TA. A pH-regulated dimeric bouquet in the structure of von Willebrand factor. EMBO J. 2011. http://dx.doi.org/10.1038/emboj.2011.297
41. Zhou YF, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2):449-458. http://dx.doi.org/10.1182/blood-2012-01-405134 PMid:22490677
42. Johnson SS, Montgomery RR, Hathaway WE. Newborn factor VIII complex: elevated activities in term infants and alterations in electrophoretic mobility related to illness and activated coagulation. Br J Haematol. 1981;47(4):597-606. http://dx.doi.org/10.1111/j.1365-2141.1981.tb02689.x PMid:6783064
43. Bauer JL, Miklos AZ, Thompson LD. Parotid gland solitary fibrous tumor: a case report and clinicopathologic review of 22 cases from the literature. Head and neck pathology. 2012;6(1):21-31. http://dx.doi.org/10.1007/s12105-011-0305-8 PMid:22002440 PMCid:3311954
44. Leyte A, Verbeet MP, Brodniewicz-Proba T, Van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem J. 1989;257(3):679-683. PMid:2494987 PMCid:1135641
45. Nesheim M, Pittman DD, Giles AR, et al. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem. 1991;266(27):17815-17820. PMid:1917924
46. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262(18):8443-8446. PMid:3110147
47. Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood. 1987;70(5):1679-1682. PMid:3117138
48. Castro-Nunez L, Bloem E, Boon-Spijker MG, et al. Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII. J Biol Chem. 2013;288(1):393-400. http://dx.doi.org/10.1074/jbc. M112.400572 PMid:23168412
49. Leyte A, van Schijndel HB, Niehrs C, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem. 1991;266(2):740-746. PMid:1898735
50. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem. 1997;272(29):18007-18014. http://dx.doi.org/10.1074/jbc.272.29.18007
51. Tuddenham EG, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol. 1982;52(2):259-267. http://dx.doi.org/10.1111/j.1365-2141.1982.tb03888.x PMid:6812613
52. Morfini M, Mannucci PM, Tenconi PM, et al. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease. Thromb Haemost. 1993;70(2):270-272. PMid:8236134
53. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood. 1989;74(5):1591-1599. PMid:2506947
54. Jacquemin M. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions. Acta haematologica. 2009;121(2-3):102-105. http://dx.doi.org/10.1159/000214849 PMid:19506355
55. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5(7):1353-1360. http://dx.doi.org/10.1111/j.1538-7836.2007.02572.x PMid:17425686
56. Weiss HJ, Sussman, II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60(2):390-404. http://dx.doi.org/10.1172/JCI108788 PMid:17621 PMCid:372380
57. Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem/FEBS. 1990;189(2):229-234. http://dx.doi.org/10.1111/j.1432-1033.1990.tb15481.x
58. Fay PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem. 1991;266(4):2172-2177. PMid:1846615
59. Lenting PJ, Donath MJ, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem. 1994;269(10):7150-7155. PMid:8125924
60. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemostas. 1996;76(5):749-754. PMid:8950785
61. Amano K, Arai M, Koshihara K, et al. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex. Am J Hematol. 1995;49(4):310-317. http://dx.doi.org/10.1002/ajh.2830490409 PMid:7639276
62. Gensana M, Altisent C, Aznar JA, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia. 2001;7(4):369-374. http://dx.doi.org/10.1046/j.1365-2516.2001.00526.x PMid:11442641
63. Shi Q, Kuether EL, Schroeder JA, et al. Factor VIII inhibitors: von willebrand factor makes a difference in vitro and in vivo. J Thromb Haemostas. 2012.
64. Lenting PJ, Neels JG, van den Berg BM, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999;274(34):23734-23739. http://dx.doi.org/10.1074/jbc.274.34.23734 PMid:10446132
65. Dasgupta S, Navarrete AM, Bayry J, et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2007;104(21):8965-8970. http://dx.doi.org/10.1073/pnas.0702120104 PMid:17502612 PMCid:1885611
66. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemostas. 2002;88(2):221-229. PMid:12195693
67. Delignat S, Repesse Y, Navarrete AM, et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia. 2012;18(2):248-254. http://dx.doi.org/10.1111/j.1365-2516.2011.02679.x PMid:22044692
68. Meeks SL, Cox CL, Healey JF, et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood. 2012;120(12):2512-2520. http://dx.doi.org/10.1182/blood-2012-02-412361 PMid:22855607
69. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4693-4697. http://dx.doi.org/10.1182/blood-2006-11-056317 PMid:17218379
70. Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Eng J Med. 2013;368(3):231-239. http://dx.doi.org/10.1056/NEJMoa1208024 PMid:23323899
71. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006;107(1):46-51. http://dx.doi.org/10.1182/blood-2005-04-1371 PMid:16166584
72. Goudemand J. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates. Haemophilia. 2007;13 Suppl 5:47-51. http://dx.doi.org/10.1111/j.1365-2516.2007.01571.x PMid:18078397
73. Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemostas. 2010;104(5):931-940. http://dx.doi.org/10.1160/TH10-03-0151 PMid:20838738
74. Kawasaki T, Kaida T, Arnout J, Vermylen J, Hoylaerts MF. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic. Thromb Haemost. 1999;81(2):306-311. PMid:10064011
75. Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007;109(6):2424-2429. http://dx.doi.org/10.1182/blood-2006-06-028241 PMid:17119108 PMCid:1852205
76. Holmberg HL, Kjalke M, Karpf D, et al. High Affinity Binding of FVIII to VWF Is Not Required for the Haemostatic Effect of FVIII In Vivo. ASH Annual Meeting Abstracts. 2011;118:1182.
77. Nyman D. Interaction of collagen with the factor VIII antigen-activity - von Willebrand factor complex. Thromb Res. 1977;11(3):433-438. http://dx.doi.org/10.1016/0049-3848(77)90196-7
78. Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J Biol Chem. 1995;270(18):10822-10827. http://dx.doi.org/10.1074/jbc.270.18.10822 PMid:7738019
79. Lankhof H, van Hoeij M, Schiphorst ME, et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost. 1996;75(6):950-958. PMid:8822592
80. Romijn RA, Westein E, Bouma B, et al. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem. 2003;278(17):15035-15039. http://dx.doi.org/10.1074/jbc. M208977200 PMid:12582178
81. Nishida N, Sumikawa H, Sakakura M, et al. Collagen-binding mode of vWF-A3 domain determined by a transferred cross- saturation experiment. Nature Struc Biol. 2003;10(1):53-58. http://dx.doi.org/10.1038/nsb876 PMid:12447349
82. Santoro SA. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res. 1981;21(6):689-691. http://dx.doi.org/10.1016/0049-3848(81)90272-3
83. Denis C, Baruch D, Kielty CM, Ajzenberg N, Christophe O, Meyer D. Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. Arterioscler Thromb. 1993;13(3):398-406. http://dx.doi.org/10.1161/01.ATV.13.3.398 PMid:8443144
84. Lisman T, Raynal N, Groeneveld D, et al. A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides. Blood. 2006;108(12):3753-3756. http://dx.doi.org/10.1182/blood-2006-03-011965 PMid:16912226
85. Brondijk TH, Bihan D, Farndale RW, Huizinga EG. Implications for collagen I chain registry from the structure of the collagen von Willebrand factor A3 domain complex. Proc Natl Acad Sci U S A. 2012;109(14):5253-5258. http://dx.doi.org/10.1073/pnas.1112388109 PMid:22440751 PMCid:3325688
86. Ribba AS, Loisel I, Lavergne JM, et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost. 2001;86(3):848-854. PMid:11583318
87. Riddell AF, Gomez K, Millar CM, et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood. 2009;114(16):3489-3496. http://dx.doi.org/10.1182/blood-2008-10-184317 PMid:19687512
88. Flood VH, Lederman CA, Wren JS, et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost. 2010;8(6):1431-1433. http://dx.doi.org/10.1111/j.1538-7836.2010.03869.x PMid:20345715
89. Legendre P, Navarrete AM, Rayes J, et al. Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood. 2013;121(11):2135-2143. http://dx.doi.org/10.1182/blood-2012-09-456038 PMid:23335371
90. Pareti FI, Fujimura Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem. 1986;261(32):15310-15315. PMid:3490481
91. Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem. 1987;262(28):13835-13841. PMid:3498719
92. Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem. 1989;264(29):17361-17367. PMid:2477370
93. Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermylen J. von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem J. 1997;324 (Pt 1):185-191. PMid:9164855 PMCid:1218415
94. Bonnefoy A, Romijn RA, Vandervoort PA, Van Rompaey I, Vermylen J, Hoylaerts MF. von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen. J Thromb Haemost. 2006;4(10):2151-2161. http://dx.doi.org/10.1111/j.1538-7836.2006.02111.x PMid:16805860
95. Morales LD, Martin C, Cruz MA. The interaction of von Willebrand factor-A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen. J Thromb Haemostas. 2006;4(2):417-425. http://dx.doi.org/10.1111/j.1538-7836.2006.01742.x PMid:16420575
96. Flood VH, Gill JC, Christopherson PA, et al. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemostas. 2012;10(7):1417-1424. http://dx.doi.org/10.1111/j.1538-7836.2012.04746.x PMid:22507569
97. McKinnon TA, Nowak AA, Cutler J, Riddell AF, Laffan MA, Millar CM. Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion. J Thromb Haemostas. 2012;10(7):1409-1416. http://dx.doi.org/10.1111/j.1538-7836.2012.04760.x PMid:22537243
98. Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. Haemophilia. 2013;DOI:10.1111/hae.12117. http://dx.doi.org/10.1111/hae.12117
99. Marx I, Lenting PJ, Adler T, Pendu R, Christophe OD, Denis CV. Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants. Arterioscler Thromb Vasc Biol. 2008;28(3):419-424. http://dx.doi.org/10.1161/ATVBAHA.107.159442 PMid:18187670
100. Marx I, Christophe OD, Lenting PJ, et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood. 2008;112(3):603-609. http://dx.doi.org/10.1182/blood-2008-02-142943 PMid:18487513
101. Wu D, Vanhoorelbeke K, Cauwenberghs N, et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99(10):3623-3628. http://dx.doi.org/10.1182/blood. V99.10.3623 PMid:11986216
102. Navarrete AM, Casari C, Legendre P, et al. A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. Blood. 2012;120(13):2723-2732. http://dx.doi.org/10.1182/blood-2012-03-420042 PMid:22915646
103. Sixma JJ, van Zanten GH, Huizinga EG, et al. Platelet adhesion to collagen: an update. Thromb Haemostas. 1997;78(1):434-438. PMid:9198192
104. Nuyttens BP, Thijs T, Deckmyn H, Broos K. Platelet adhesion to collagen. Thromb Res. 2011;127 Suppl 2:S26-29. http://dx.doi.org/10.1016/S0049-3848(10)70151-1
105. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102(2):449-461. http://dx.doi.org/10.1182/blood-2002-12-3882 PMid:12649139
106. Inoue O, Suzuki-Inoue K, Ozaki Y. Redundant mechanism of platelet adhesion to laminin and collagen under flow: involvement of von Willebrand factor and glycoprotein Ib-IX-V. J Biol Chem. 2008;283(24):16279-16282. http://dx.doi.org/10.1074/jbc. C700241200 PMid:18450753
107. Schaff M, Receveur N, Bourdon C, et al. Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol. 2011;31(1):117-124. http://dx.doi.org/10.1161/ATVBAHA.110.206375 PMid:20651280
108. Ruggeri ZM. Platelet adhesion under flow. Microcirculation. 2009;16(1):58-83. http://dx.doi.org/10.1080/10739680802651477 PMid:19191170 PMCid:3057446
109. Bendetowicz AV, Wise RJ, Gilbert GE. Collagen-bound von Willebrand factor has reduced affinity for factor VIII. J Biol Chem. 1999;274(18):12300-12307. http://dx.doi.org/10.1074/jbc.274.18.12300 PMid:10212199
110. Lopez JA, Dong JF. Structure and function of the glycoprotein Ib-IX-V complex. Curr Opin Hematol. 1997;4(5):323-329. http://dx.doi.org/10.1097/00062752-199704050-00005
111. Andrews RK, Shen Y, Gardiner EE, Dong JF, Lopez JA, Berndt MC. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemostas. 1999;82(2):357-364. PMid:10605725
112. Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176-1179. http://dx.doi.org/10.1126/science.107355 PMid:12183630
113. Dumas JJ, Kumar R, McDonagh T, et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem. 2004;279(22):23327-23334. http://dx.doi.org/10.1074/jbc. M401659200 PMid:15039442
114. Ruggeri ZM, Zarpellon A, Roberts JR, Mc Clintock RA, Jing H, Mendolicchio GL. Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. Thromb Haemostas. 2010;104(5):894-902. http://dx.doi.org/10.1160/TH10-09-0578 PMid:20941453
115. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol. 2003;10(2):142-149. http://dx.doi.org/10.1097/00062752-200303000-00008 PMid:12579041
116. Andrews RK, Berndt MC. Platelet adhesion: a game of catch and release. J Clin Invest. 2008;118(9):3009-3011. PMid:18725992 PMCid:2518077
117. Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemostas. 2008;99(2):264-270. PMid:18278173
118. Fressinaud E, Baruch D, Girma JP, Sakariassen KS, Baumgartner HR, Meyer D. von Willebrand factor-mediated platelet adhesion to collagen involves platelet membrane glycoprotein IIb-IIIa as well as glycoprotein Ib. J Lab Clin Med. 1988;112(1):58-67. PMid:2455762
119. Beacham DA, Wise RJ, Turci SM, Handin RI. Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site-directed mutagenesis. J Biol Chem. 1992;267(5):3409-3415. PMid:1737795
120. Danton MC, Zaleski A, Nichols WL, Olson JD. Monoclonal antibodies to platelet glycoproteins Ib and IIb/IIIa inhibit adhesion of platelets to purified solid-phase von Willebrand factor. J Lab Clin Med. 1994;124(2):274-282. PMid:8051492
121. Lankhof H, Wu YP, Vink T, et al. Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor. Blood. 1995;86(3):1035-1042. PMid:7620157
122. Zanardelli S, Chion AC, Groot E, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood. 2009;114(13):2819-2828. http://dx.doi.org/10.1182/blood-2009-05-224915 PMid:19587373 PMCid:3402367
123. Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus EM, Sadler JE. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost. 2009;7(12):2088-2095. http://dx.doi.org/10.1111/j.1538-7836.2009.03620.x PMid:19765212
124. Zannettino AC, Holding CA, Diamond P, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005;204(2):714-723. http://dx.doi.org/10.1002/jcp.20354 PMid:15799029
125. Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe OD. Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost. 2007;5(9):1956-1962. http://dx.doi.org/10.1111/j.1538-7836.2007.02681.x PMid:17723135
126. Vinholt PJ, Overgaard M, Diederichsen AC, et al. An ELISA for the quantitation of von Willebrand Factor: Osteoprotegerin complexes in plasma. Thromb Res. 2013;DOI:10.1016/j.thromres.2013.03.001. http://dx.doi.org/10.1016/j.thromres.2013.03.001
127. Saint-Lu N, Oortwijn BD, Pegon JN, et al. Identification of Galectin-1 and Galectin-3 as Novel Partners for Von Willebrand Factor. Arterioscler Thromb Vasc Biol. 2012;32(4):894-901. http://dx.doi.org/10.1161/ATVBAHA.111.240309 PMid:22267483
128. Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PloS one. 2013;8(3):e59372. http://dx.doi.org/10.1371/journal.pone.0059372 PMid:23555663 PMCid:3612042
129. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529. http://dx.doi.org/10.1073/pnas.95.16.9524 PMid:9689113 PMCid:21371
130. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol. 2004;126(2):213-218. http://dx.doi.org/10.1111/j.1365-2141.2004.05009.x PMid:15238142
131. Denis CV, Christophe OD, Oortwijn BD, Lenting PJ. Clearance of von Willebrand factor. Thromb Haemost. 2008;99(2):271-278. PMid:18278174
132. Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81(1):8-13. PMid:10348715
133. Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A. 2008;105(21):7416-7421. http://dx.doi.org/10.1073/pnas.0801735105 PMid:18492805 PMCid:2396690
134. Franchini M, Mannucci PM. Von Willebrand disease-associated angiodysplasia: a few answers, still many questions. Br J Haematol. 2013;161(2):177-182. http://dx.doi.org/10.1111/bjh.12272 PMid:23432086
135. Franchini M, Frattini F, Crestani S, Bonfanti C, Lippi G. von Willebrand factor and cancer: A renewed interest. Thromb Res. 2013;131(4):290-292. http://dx.doi.org/10.1016/j.thromres.2013.01.015 PMid:23394808
136. Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071-1080. http://dx.doi.org/10.1182/blood-2010-01-264507 PMid:21048155 PMCid:3035068
137. Liu FT, Yang RY, Hsu DK. Galectins in acute and chronic inflammation. Ann N Y Acad Sci. 2012;1253:80-91. http://dx.doi.org/10.1111/j.1749-6632.2011.06386.x PMid:22329844
138. Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F. Galectins and gliomas. Brain Pathol. 2010;20(1):17-27. http://dx.doi.org/10.1111/j.1750-3639.2009.00270.x PMid:19371355 PMCid:2805916
139. Pi L, Shenoy AK, Liu J, et al. CCN2/CTGF regulates neovessel formation via targeting structurally conserved cystine knot motifs in multiple angiogenic regulators. FASEB J. 2012. http://dx.doi.org/10.1096/fj.11-200154 PMid:22611085
140. van Breevoort D, van Agtmaal EL, Dragt BS, et al. Proteomic screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. J Proteome Res. 2012;11(5):2925-2936. http://dx.doi.org/10.1021/pr300010r PMid:22468712
141. Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost. 1993;70(3):546. PMid:8259565
142. Park SO, Wankhede M, Lee YJ, et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest. 2009;119(11):3487-3496. PMid:19805914 PMCid:2769195
143. Castaman G, Federici AB, Tosetto A, et al. Different bleeding risk in type 2 A and 2 M Von Willebrand disease: a two-year prospective study in 107 patients. J Thromb Haemost. 2012.
144. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349(4):343-349. http://dx.doi.org/10.1056/NEJMoa022831 PMid:12878741
145. Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res. 2010;3(6):618-624. http://dx.doi.org/10.1007/s12265-010-9222-6 PMid:20835786
146. Giddings JC, Banning AP, Ralis H, Lewis MJ. Redistribution of von Willebrand factor in porcine carotid arteries after balloon angioplasty. Arterioscler Thromb Vasc Biol. 1997;17(10):1872-1878. http://dx.doi.org/10.1161/01.ATV.17.10.1872 PMid:9351348
147. Bosmans JM, Kockx MM, Vrints CJ, Bult H, De Meyer GR, Herman AG. Fibrin(ogen) and von Willebrand factor deposition are associated with intimal thickening after balloon angioplasty of the rabbit carotid artery. Arterioscler Thromb Vasc Biol. 1997;17(4):634-645. http://dx.doi.org/10.1161/01.ATV.17.4.634 PMid:9108775
148. De Meyer GR, Hoylaerts MF, Kockx MM, Yamamoto H, Herman AG, Bult H. Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler Thromb Vasc Biol. 1999;19(10):2524-2534. http://dx.doi.org/10.1161/01.ATV.19.10.2524 PMid:10521383
149. Qin F, Impeduglia T, Schaffer P, Dardik H. Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies. J Vasc Surg. 2003;37(2):433-439. http://dx.doi.org/10.1067/mva.2003.63 PMid:12563218
150. Zhang X, Meng H, Blaivas M, et al. Von Willebrand Factor permeates small vessels in CADASIL and inhibits smooth muscle gene expression. Transl Stroke Res. 2012;3(1):138-145. http://dx.doi.org/10.1007/s12975-011-0112-2 PMid:22639698 PMCid:3358806
151. Li S, Wang Z, Liao Y, et al. The glycoprotein Ibalpha-von Willebrand factor interaction induces platelet apoptosis. J Thromb Haemost. 2010;8(2):341-350. http://dx.doi.org/10.1111/j.1538-7836.2009.03653.x PMid:19840363
152. Terraube V, Pendu R, Baruch D, et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost. 2006;4(3):519-526. http://dx.doi.org/10.1111/j.1538-7836.2005.01770.x PMid:16405520
153. Terraube V, Marx I, Denis CV. Role of von Willebrand factor in tumor metastasis. Thromb Res. 2007;120 Suppl 2:S64-70. http://dx.doi.org/10.1016/S0049-3848(07)70132-9
154. Mochizuki S, Soejima K, Shimoda M, et al. Effect of ADAM28 on Carcinoma Cell Metastasis by Cleavage of von Willebrand Factor. J Natl Cancer Inst. 2012;104(12):906-922. http://dx.doi.org/10.1093/jnci/djs232 PMid:22636800
155. Pendu R, Terraube V, Christophe OD, et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood. 2006;108(12):3746-3752. http://dx.doi.org/10.1182/blood-2006-03-010322 PMid:16926295
156. Pegon JN, Kurdi M, Casari C, et al. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica. 2012;97(12):1855-1863. http://dx.doi.org/10.3324/haematol.2012.063297 PMid:22733016 PMCid:3685284
157. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3(3):562-570. http://dx.doi.org/10.1111/j.1538-7836.2005.01122.x PMid:15748247
158. Petri B, Broermann A, Li H, et al. von Willebrand factor promotes leukocyte extravasation. Blood. 2010;116(22):4712-4719. http://dx.doi.org/10.1182/blood-2010-03-276311 PMid:20716766
159. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009;114(15):3329-3334. http://dx.doi.org/10.1182/blood-2009-03-213264 PMid:19687510 PMCid:2759655
160. Denis CV, Andre P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci U S A. 2001;98(7):4072-4077. http://dx.doi.org/10.1073/pnas.061307098 PMid:11274431 PMCid:31181
161. Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood. 2001;98(5):1424-1428. http://dx.doi.org/10.1182/blood. V98.5.1424 PMid:11520791
162. Noubade R, del Rio R, McElvany B, et al. von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encephalomyelitis. Am J Pathol. 2008;173(3):892-900. http://dx.doi.org/10.2353/ajpath.2008.080001 PMid:18688020 PMCid:2526288
163. Nichols TC, Bellinger DA, Tate DA, et al. von Willebrand factor and occlusive arterial thrombosis. A study in normal and von Willebrand's disease pigs with diet-induced hypercholesterolemia and atherosclerosis. Arteriosclerosis. 1990;10(3):449-461. http://dx.doi.org/10.1161/01.ATV.10.3.449 PMid:2344301
164. van Galen KP, Tuinenburg A, Smeets EM, Schutgens RE. Von Willebrand factor deficiency and atherosclerosis. Blood Rev. 2012;20(5):189-196. http://dx.doi.org/10.1016/j.blre.2012.05.002 PMid:22721874
165. Lenting PJ, Pegon JN, Groot E, de Groot PG. Regulation of von Willebrand factor-platelet interactions. Thromb Haemost. 2010;104(3):449-455. http://dx.doi.org/10.1160/TH09-11-0777 PMid:20539912
166. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939-2950. PMid:8874190
167. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A. 2007;104(19):7899-7903. http://dx.doi.org/10.1073/pnas.0608422104 PMid:17470810 PMCid:1876544
168. Singh I, Shankaran H, Beauharnois ME, Xiao Z, Alexandridis P, Neelamegham S. Solution structure of human von Willebrand factor studied using small angle neutron scattering. J Biol Chem. 2006;281(50):38266-38275. http://dx.doi.org/10.1074/jbc. M607123200 PMid:17052980
169. Denis CV, Lenting PJ. von Willebrand factor: at the crossroads of bleeding and thrombosis. International J Hematol. 2012;95(4):353-361. http://dx.doi.org/10.1007/s12185-012-1041-x PMid:22477538 PMCid:3677142
170. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324(5932):1330-1334. http://dx.doi.org/10.1126/science.1170905 PMid:19498171 PMCid:2753189
171. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood. 2013;121(2):270-277. http://dx.doi.org/10.1182/blood-2012-07-442285 PMid:23093621
172. Fu X, Chen J, Gallagher R, Zheng Y, Chung DW, Lopez JA. Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood. 2011;118(19):5283-5291. http://dx.doi.org/10.1182/blood-2011-01-331074 PMid:21917758 PMCid:3217410
173. Ganderton T, Berndt MC, Chesterman CN, Hogg PJ. Hypothesis for control of von Willebrand factor multimer size by intra-molecular thiol-disulphide exchange. J Thromb Haemost. 2007;5(1):204-206. http://dx.doi.org/10.1111/j.1538-7836.2006.02292.x PMid:17059432
174. Li Y, Choi H, Zhou Z, et al. Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost. 2008;6(7):1135-1143. http://dx.doi.org/10.1111/j.1538-7836.2008.02991.x PMid:18433456 PMCid:2532495
175. Yuan H, Deng N, Zhang S, et al. The unfolded von Willebrand factor response in bloodstream: the self-association perspective. J Hematol & Oncol. 2012;5:65. http://dx.doi.org/10.1186/1756-8722-5-65 PMid:23067373 PMCid:3488313
176. Rastegarlari G, Pegon JN, Casari C, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012;119(9):2126-2134. http://dx.doi.org/10.1182/blood-2011-08-373605 PMid:22234691
177. Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med. 2001;193(12):1341-1349. http://dx.doi.org/10.1084/jem.193.12.1341 PMid:11413189 PMCid:2193294
178. Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney international Supplement. 2009(112):S11-14. http://dx.doi.org/10.1038/ki.2008.610 PMid:19180123 PMCid:3158997
179. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011;118(12):3212-3221. http://dx.doi.org/10.1182/blood-2011-02-306597 PMid:21715306 PMCid:3179391
180. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585-1594. http://dx.doi.org/10.1056/NEJM199811263392203 PMid:9828246 PMCid:3159001
181. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578-1584. http://dx.doi.org/10.1056/NEJM199811263392202 PMid:9828245
182. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494. http://dx.doi.org/10.1038/35097008 PMid:11586351
183. Gandhi C, Khan MM, Lentz SR, Chauhan AK. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood. 2012;119(10):2385-2391. http://dx.doi.org/10.1182/blood-2011-09-376202 PMid:22123843 PMCid:3311260
184. Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood. 2010;115(8):1650-1653. http://dx.doi.org/10.1182/blood-2009-06-230110 PMid:19965676
185. Khan MM, Motto DG, Lentz SR, Chauhan AK. ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost. 2012;10(8):1665-1671. http://dx.doi.org/10.1111/j.1538-7836.2012.04822.x PMid:22712744
186. De Meyer SF, Schwarz T, Deckmyn H, et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report. Arterioscler Thromb Vasc Biol. 2010;30(10):1949-1951. http://dx.doi.org/10.1161/ATVBAHA.110.208918 PMid:20616311